This clinical trial is focused on studying the effects of a drug called EDP-938 on adults who have an infection caused by the Respiratory Syncytial Virus (RSV). RSV is a virus that affects the respiratory system, which includes the lungs and airways. The study is particularly interested in adults who are not hospitalized but are at high risk for complications from this infection. The purpose of the study is to evaluate how well EDP-938 works in treating RSV and to assess its safety. Participants in the study will receive either the drug EDP-938 or a placebo, which is a tablet that looks like the drug but does not contain the active ingredient.

During the study, participants will take the medication in the form of a coated tablet by mouth. The study will monitor the progression of RSV infection by looking at clinical symptoms, which are the signs and feelings of illness that participants experience. The study will last for a period of time, and participants will be asked to report on their symptoms and any changes they notice. The study aims to understand how quickly symptoms of RSV improve and how the drug affects the overall health and daily activities of the participants.

The study will also look at the safety of EDP-938 by monitoring any side effects or adverse events that participants may experience. This includes checking vital signs, which are basic measures of health like heart rate and blood pressure, and conducting laboratory tests. The information gathered from this study will help determine if EDP-938 is an effective and safe treatment option for people with RSV who are at high risk for complications.